SCHEMBL5618710

SCHEMBL5618710

CNc1nccn2c(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)cnc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.65
▸ AURKB Q96GD4 1/20 0.65
▸ FLT3 P36888 2/20 0.54
▸ GAA P10253 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ USP2 O75604 1/20 0.45
▸ MAPKAPK5 Q8IW41 1/20 0.44
▸ TTK P33981 2/20 0.44
▸ HPGD P15428 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NAMPT P43490 1/20 0.42
▸ IKBKB O14920 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24105040 0.84 AURKA (0.74) AURKAAURKBFLT3GAAALDH1A1
SCHEMBL5618052 0.83 AURKA (0.47) AURKAAURKBFLT3MAPKAPK5TTK
SCHEMBL5617872 0.81 FLT3 (0.52) AURKAAURKBFLT3TTK
SCHEMBL14507445 0.79 AURKB (1.00) AURKAAURKBFLT3MAPKAPK5
SCHEMBL5618232 0.77 TTK (0.52) FLT3MAPKAPK5TTK
SCHEMBL5394701 0.76 SRC (0.53) FLT3
SCHEMBL5618784 0.75 TTK (0.52) FLT3ALDH1A1KDM4EMAPKAPK5TTK
SCHEMBL8241167 0.74 AURKA (0.59) AURKAAURKBPOLBKMT2AMEN1
SCHEMBL5618421 0.74 TTK (0.50) AURKAAURKBFLT3KMT2AMEN1
SCHEMBL5412371 0.74 CD274 (0.62) TTKHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 AURKA 215/4885AURKB 332/4885FLT3 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback